Table S1.
Comparison between HEK samples and clinical material for subset of nine antibodies
| Name | PSR | AC-SINS (Dlmax) | Fab Tm, °C | CIC, min | HIC RT, min | ELISA | BVP | SMAC RT, min | SGAC100 | AS | CSI-BLI, nm | Constant region comments |
| Clinical samples | ||||||||||||
| Infliximab | 0.00 | 30.04 | 65.0 | 8.70 | 10.20 | 0.89 | 1.21 | 8.84 | 0.00 | 0.07 | 0.05 | IgG1 [CH3] |
| Golimumab | 0.23 | 30.04 | 70.0 | 11.16 | 11.65 | 0.98 | 1.81 | 12.06 | 0.00 | 0.00 | 0.00 | IgG1 |
| Pembrolizumab | 0.26 | 30.04 | 65.5 | 10.42 | 11.17 | 2.04 | 4.12 | 13.23 | 0.00 | 0.02 | −0.04 | IgG4 |
| Vedolizumab | 0.00 | 1.30 | 80.5 | 8.93 | 10.91 | 1.08 | 2.95 | 12.11 | 500.00 | 0.00 | −0.02 | IgG1 [lower hinge] |
| Rituximab | 0.39 | 2.03 | 74.0 | 9.99 | 10.82 | 1.11 | 4.12 | 9.08 | 700.00 | 0.02 | 0.00 | IgG1 [CH1] |
| Adalimumab | 0.00 | 1.26 | 74.5 | 8.81 | 8.82 | 1.09 | 1.31 | 8.65 | 1000.00 | 0.00 | −0.02 | IgG1 |
| Denosumab | 0.01 | 6.71 | 73.0 | 8.63 | 8.37 | 1.14 | 1.13 | 8.67 | 900.00 | 0.00 | −0.03 | IgG2 |
| Ipilimumab | 0.21 | 7.50 | 77.0 | 10.81 | 11.57 | 1.00 | 1.91 | 12.11 | 300.00 | 0.00 | −0.01 | IgG1 [CH1] |
| Bevacizumab | 0.00 | 1.53 | 73.5 | 9.82 | 11.75 | 1.51 | 4.76 | 11.00 | 600.00 | 0.14 | −0.02 | IgG1 [CH3] |
| HEK samples with matching variable region sequences (data from Dataset S3) | Isotype | |||||||||||
| Infliximab | 0.00 | 29.65 | 64.5 | 9.01 | 10.36 | 1.04 | 1.37 | 8.89 | 0.00 | 0.18 | 0.05 | IgG1 |
| Golimumab | 0.23 | 22.97 | 70.0 | 11.23 | 11.36 | 1.31 | 2.71 | 12.75 | 0.00 | 0.06 | −0.01 | |
| Pembrolizumab | 0.30 | 5.62 | 66.0 | 10.92 | 11.07 | 1.28 | 2.23 | 13.48 | 500.00 | 0.03 | 0.01 | |
| Vedolizumab | 0.00 | 0.39 | 80.5 | 8.99 | 10.94 | 1.15 | 1.58 | 12.31 | 600.00 | 0.07 | −0.02 | |
| Rituximab | 0.38 | 2.13 | 69.0 | 10.15 | 10.80 | 1.19 | 2.93 | 9.11 | 700.00 | 0.03 | −0.01 | |
| Adalimumab | 0.00 | 1.06 | 71.0 | 8.87 | 8.82 | 1.08 | 1.49 | 8.67 | 900.00 | 0.05 | −0.01 | |
| Denosumab | 0.00 | 5.91 | 69.5 | 8.81 | 8.50 | 5.92 | 17.75 | 8.60 | 1,000.00 | 0.01 | 0.11 | |
| Ipilimumab | 0.23 | 10.41 | 73.0 | 10.94 | 11.57 | 1.05 | 1.69 | 12.98 | 400.00 | 0.04 | 0.01 | |
| Bevacizumab | 0.00 | 0.79 | 63.5 | 9.82 | 11.77 | 1.29 | 2.78 | 11.07 | 700.00 | 0.22 | −0.02 | |
Assay values highlighted in bold are those that exceed the thresholds defined in Table 1. Differences in the constant regions of the heavy chain or the isotype are highlighted in italics in the last column.